Kwang Dong Pharmaceutical Co., Ltd. (KRX: 009290)
South Korea
· Delayed Price · Currency is KRW 5,280.00
+140.00 (2.72%)
Nov 15, 2024, 3:30 PM KST
Kwang Dong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Other Revenue | 0 | - | - | -0 | - | - | Upgrade
|
| Revenue | 1,607,444 | 1,514,454 | 1,431,545 | 1,338,182 | 1,243,770 | 1,238,255 | Upgrade
|
| Revenue Growth (YoY) | 7.90% | 5.79% | 6.98% | 7.59% | 0.45% | 4.92% | Upgrade
|
| Cost of Revenue | 1,304,754 | 1,216,563 | 1,151,550 | 1,065,870 | 987,672 | 981,702 | Upgrade
|
| Gross Profit | 302,690 | 297,891 | 279,995 | 272,312 | 256,098 | 256,553 | Upgrade
|
| Selling, General & Admin | 242,149 | 233,331 | 225,167 | 213,458 | 196,462 | 201,578 | Upgrade
|
| Research & Development | 13,942 | 15,275 | 9,678 | 8,322 | 5,957 | 5,339 | Upgrade
|
| Other Operating Expenses | 2,311 | 1,989 | 1,391 | 1,589 | 2,857 | 2,655 | Upgrade
|
| Operating Expenses | 266,292 | 255,821 | 241,751 | 227,376 | 209,507 | 214,750 | Upgrade
|
| Operating Income | 36,398 | 42,070 | 38,244 | 44,936 | 46,591 | 41,803 | Upgrade
|
| Interest Expense | -8,883 | -6,904 | -3,735 | -2,544 | -2,539 | -3,177 | Upgrade
|
| Interest & Investment Income | 7,318 | 5,399 | 2,844 | 2,415 | 2,850 | 2,615 | Upgrade
|
| Earnings From Equity Investments | -26.26 | -429.82 | -435.51 | -112.22 | -62.65 | -41.36 | Upgrade
|
| Currency Exchange Gain (Loss) | -11.72 | -384.81 | 6.49 | 693.27 | -800.07 | 1,051 | Upgrade
|
| Other Non Operating Income (Expenses) | -311.74 | -179.12 | 1,132 | -865.71 | 932.94 | -895.86 | Upgrade
|
| EBT Excluding Unusual Items | 34,483 | 39,571 | 38,056 | 44,522 | 46,972 | 41,355 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13,049 | 9,412 | -1,932 | -10,232 | 17,536 | 548.99 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1,260 | -1,964 | 166.52 | 38.87 | 1,178 | 277.76 | Upgrade
|
| Asset Writedown | - | - | - | - | -2,735 | -5,412 | Upgrade
|
| Pretax Income | 50,792 | 49,019 | 36,291 | 34,329 | 62,951 | 36,770 | Upgrade
|
| Income Tax Expense | 15,329 | 9,648 | 9,590 | 8,788 | 17,349 | 14,114 | Upgrade
|
| Earnings From Continuing Operations | 35,463 | 39,372 | 26,701 | 25,541 | 45,602 | 22,656 | Upgrade
|
| Minority Interest in Earnings | -1,576 | -2,406 | -2,527 | -1,522 | -232.19 | 402.51 | Upgrade
|
| Net Income | 33,887 | 36,966 | 24,174 | 24,019 | 45,370 | 23,058 | Upgrade
|
| Net Income to Common | 33,887 | 36,966 | 24,174 | 24,019 | 45,370 | 23,058 | Upgrade
|
| Net Income Growth | -6.36% | 52.91% | 0.64% | -47.06% | 96.76% | 3.19% | Upgrade
|
| Shares Outstanding (Basic) | 40 | 40 | 41 | 41 | 41 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 40 | 40 | 41 | 41 | 41 | 40 | Upgrade
|
| Shares Change (YoY) | -2.19% | -1.48% | -0.11% | 1.48% | 2.24% | -2.29% | Upgrade
|
| EPS (Basic) | 845.54 | 913.39 | 588.45 | 584.68 | 1119.49 | 581.72 | Upgrade
|
| EPS (Diluted) | 845.10 | 913.00 | 588.00 | 584.33 | 1119.00 | 581.72 | Upgrade
|
| EPS Growth | -4.23% | 55.27% | 0.63% | -47.78% | 92.36% | 5.61% | Upgrade
|
| Free Cash Flow | -105,246 | -46,515 | 37,439 | 31,145 | 17,566 | 16,648 | Upgrade
|
| Free Cash Flow Per Share | -2626.07 | -1149.35 | 911.36 | 757.27 | 433.44 | 420.00 | Upgrade
|
| Dividend Per Share | 100.000 | 100.000 | 100.000 | 100.000 | 100.000 | 80.000 | Upgrade
|
| Dividend Growth | 0% | 0% | 0% | 0% | 25.00% | 0% | Upgrade
|
| Gross Margin | 18.83% | 19.67% | 19.56% | 20.35% | 20.59% | 20.72% | Upgrade
|
| Operating Margin | 2.26% | 2.78% | 2.67% | 3.36% | 3.75% | 3.38% | Upgrade
|
| Profit Margin | 2.11% | 2.44% | 1.69% | 1.79% | 3.65% | 1.86% | Upgrade
|
| Free Cash Flow Margin | -6.55% | -3.07% | 2.62% | 2.33% | 1.41% | 1.34% | Upgrade
|
| EBITDA | 50,208 | 54,974 | 52,262 | 59,045 | 66,299 | 60,605 | Upgrade
|
| EBITDA Margin | 3.12% | 3.63% | 3.65% | 4.41% | 5.33% | 4.89% | Upgrade
|
| D&A For EBITDA | 13,810 | 12,904 | 14,017 | 14,110 | 19,709 | 18,802 | Upgrade
|
| EBIT | 36,398 | 42,070 | 38,244 | 44,936 | 46,591 | 41,803 | Upgrade
|
| EBIT Margin | 2.26% | 2.78% | 2.67% | 3.36% | 3.75% | 3.38% | Upgrade
|
| Effective Tax Rate | 30.18% | 19.68% | 26.43% | 25.60% | 27.56% | 38.38% | Upgrade
|
| Advertising Expenses | - | 46,186 | 42,214 | 40,464 | 37,872 | 44,725 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.